Objectives: We will describe insulin and C-peptide levels observed in sulfonylurea-induced hypoglycemia and determine whether these levels differed if obtained before or after hypoglycemic therapy.
INTRODUCTION
Measurement of insulin and C-peptide levels may be employed in the investigation of an unknown cause of hypoglycemia. When insulin is secreted, equimolar amounts of insulin and C-peptide (the peptide fragment cleaved from proinsulin) are released into circulation [1] . Increased endogenous insulin secretion is associated with increased C-peptide secretion, whereas insulin levels are high and C-peptide levels low with exogenous insulin administration [2, 1] . Thus, serum insulin and C-peptide measurements may be exploited to differentiate between endogenous (insulinoma or medications that stimulate insulin secretion) and exogenous (insulin administration) insulin sources. Because sulfonylurea medications stimulate the secretion of insulin, and necessarily C-peptide, sulfonylurea-induced hypoglycemia may mimic hypoglycemia caused by an insulinoma [2] [3] [4] [5] [6] .
Many medical texts and published algorithms tell us sulfonylurea-induced hypoglycemia yields insulin and C-peptide levels that are "high" or "elevated," but the texts and published algorithms fail to provide details; such as the magnitude of the effect and the effect of hypoglycemic treatment on expected values [3, [7] [8] [9] Other authors provide suggested cut-off values for insulin and C-peptide without reference to values actually observed [4] [5] [6] 10, 11] . The primary purpose of this study was to describe the range of observed values for these variables in sulfonylureainduced hypoglycemia and determine whether these variables differed if levels were obtained before or after hypoglycemic therapy was administered. We accomplished this aim by performing a systematic review of the English literature to identify cases that report measured serum glucose, insulin, and C-peptide levels associated with sulfonylurea-induced hypoglycemia.
METHODS
We performed asystematic review of the English literature from 1970 (C-peptide assay first described) through March 2004 [12] . The Ovid search engine (Ovid Technologies™, 2000 -2003 was used to search the Medline database. Our Medical Subject Headings (MeSH) included the following: "hypoglycemia" AND "sulfonylurea compounds" OR "C-peptide" OR "insulin," OR the text words "hypoglycemi$" AND "sulfonylurea$," OR "C-peptide," OR "insulin" for human exposures. A broad search was used because articles identified before the search was initiated had variable MeSH headings. But nearly all were categorized under "hypoglycemia" and/or "sulfonylurea compounds," "C-peptide", or "insulin." The search criteria identified eleven thousand forty-two articles.
The primary author reviewed the titles and/or abstracts of all articles retrieved by the search. We included articles if hypoglycemia was due to sulfonylureas (confirmed by history or laboratory analysis) and if insulin and C-peptide levels were obtained at the time of documented hypoglycemia (blood glucose of Ͻ60 mg/dL (3.3 mmol/L) via bedside glucometer or venous sampling). We excluded articles if cases involved another hypoglycemic agent in addition to a sulfonylurea, as well as patients with hepatic or renal failure because insulin is mainly cleared by the liver and C-peptide by the kidney [9, 13, 14] . The primary author reviewed, in full, the articles that were unable to be included or excluded based on title or abstract.
All authors reviewed articles that met the inclusion criteria to confirm inclusion criteria and to classify patients into groups; (1) those who had "sets" obtained BEFORE hypoglycemic therapy, or (2) those who had "sets" AFTER hypoglycemic therapy. A "set" was defined as blood glucose (Ͻ60 mg/dL; 3.3 mmol/L), insulin, and C-peptide levels that were obtained at the same time.
Hypoglycemic therapy included administration of oral or intravenous glucose, glucagon, octreotide, or diazoxide. If it was unknown or unclear when hypoglycemic therapy was administered compared to when "sets" were obtained, they were included in a third UNKNOWN group. The algorithm for article acquisition is shown in Figure 1 .
Levels reported in SI units were converted to conventional units using the following conversions; glucose: mmol/L ϭ 0.0555 mg/dL; insulin: pmol/L ϭ 6.945 IU/mL; nmol/L ϭ 0.333 ng/mL.
Statistical Analysis: All analyses were done using GraphPad Instat version 3.06 (© 1992-2003 GraphPad Software, Inc.). For all articles meeting inclusion criteria, we performed descriptive statistics using all patients and all "sets" of levels. Additionally, descriptive statistics were performed on each group, (BEFORE therapy, AFTER therapy, and UNKNOWN). However, the articles did not provide the ages and sex of many patients. Additionally, several glucose, insulin, and C-peptide levels were reported as non-exact levels (such as values reported as Ͻ or Ͼ). These levels are not included in mean or median calculations, but they are included in range descriptions.
RESULTS
Through the Ovid search, we identified 19 articles that met the inclusion criteria. Reference lists of these 19 articles were handsearched, and 4 additional articles meeting inclusion criteria were found: this yielded 23 articles. One article by Hussain et al. was excluded by group consensus because we were unable to determine which blood glucose measurements corresponded to reported insulin and C-peptide levels [16] . This yielded a total of 22 articles. The articles provided cases of 76 patients with 97 "sets" of levels that met inclusion criteria. All authors agreed on the classification of each case into the BEFORE, AFTER or UNKNOWN groups. Information for all included articles and cases is shown in Table 1 .
A single C-peptide value (in the BEFORE therapy group) was reported as 12,100 ng/mL [20] . This level was 270 times higher than the next highest level, and considered erroneous by the authors. It was excluded from all calculations, but it is shown in Table 1 for completeness. Finally, the article by Hampton et al. reported only mean glucose, insulin, and C-peptide levels of 3 patients. These levels are not included in descriptive statistics, but they are included in Table 1 . Table 2 shows the descriptive statistics of all articles that met inclusion criteria, and Table 3 shows the statistics of the BEFORE, AFTER, and UNKNOWN groups. There is a wide variation in reported insulin and C-peptide levels in sulfonylurea-induced hypoglycemia. Although glucose, insulin, and C-peptide levels tended to be higher in the AFTER therapy group, there was wide overlap with results in the BEFORE therapy group.
DISCUSSION
Although the medical literature tells us insulin and C-peptide levels are elevated in sulfonylurea-induced hypoglycemia, there is a lack of information regarding levels that are actually observed [3, 7, 8] . However, we must first understand what actually constitutes an "elevated" insulin or C-peptide level in a hypoglycemic setting. It is not that levels are above normal fasting ranges, but they are relatively greater than what would be expected at a given blood glucose level. Normal fasting ranges do not apply to hypoglycemic patients [10, 11] . As blood glucose levels fall around 45-60 mg/dL, insulin and C-peptide secretion nearly ceases [3, 17, 38] . Failure to suppress insulin and C-peptide secretion, in the setting of hypoglycemia, indicates inappropriate endogenous insulin secretion.
We must also realize that laboratories utilize different assay techniques. Older polyclonal insulin assays cross-react with proinsulin and insulin precursors, yielding insulin levels higher than the newer monoclonal assays [4, 9, 14] . However, there is still a large amount of variability in the sensitivity and cross-reactivity of monoclonal assays, and universally accepted levels for the Comments: Levels were drawn during a 100 g oral glucose tolerance test after an overnight fast. The first "set" of levels was obtained at the same time glucose was given, and thus considered BEFORE therapy. Subsequent levels were obtained every 30 minutes thereafter and are included in the AFTER therapy group.
Comments: Born with hypoglycemia. Levels drawn 3 hours after birth while receiving glucose and octreotide infusions. Three additional complete "sets" were drawn, but excluded because glucose Ն 60 mg/dL. Five incomplete "sets" excluded (no insulin level obtained).
Comments: 10% dextrose infusion was held for "a short time." The patient then became symptomatic and these levels were drawn.
Comments: Received 1 mg IM glucagon 1 hour before levels drawn, and was eating "sugary" foods when levels drawn.
Comments: Receiving "continuous dextrose infusion" when levels drawn.
Comments:
Receiving "continuous intravenous glucose infusion" when levels drawn. Comments: These levels were drawn at 30 minute intervals after oral glucose administered.
May have been receiving glucose infusion when levels drawn, but unclear.
Comments: Unknown if patients received therapy before levels drawn. Exact levels for each patient are unknown.
Comments: Unknown if patient received therapy before levels drawn. Comments: Five additional complete "sets" were drawn, but excluded because glucose Ն 60 mg/dL. Two incomplete "sets" excluded (no insulin level obtained). These two "sets" are from the same patient.
These two "sets" are from the same patient.
These three "sets" are from the same patient.
Intent not provided for cases. Four patients had diabetes (one patient on glyburide). Three patients took their wife's medication. Two patients given wrong medication.
One patient living with a diabetic. Remainder unclear.
Comments: Unknown if patients received therapy before levels were drawn. Five additional patients listed in article, but 1 was excluded because of no accompanying insulin level, one excluded because of renal failure, and 3 excluded because of glucose Ն 60 mg/dL.
Unknown if patient received therapy before levels were drawn.
Not provided diagnosis of hyperinsulinism in a hypoglycemic setting have not been established [14] . Author opinions and assay methods vary when it comes to suggested insulin and C-peptide cut-off levels needed to diagnose endogenous insulin hypersecretion. And it should be noted that these opinions fail to provide reference to actual values obtained in sulfonylurea-induced hypoglycemia. Service recommends using insulin levels Ն6 IU/mL (41.7 pmol/L) using a double-antibody radioimmunoassay (or Ն3 IU/mL (20.8 pmol/L) using a immunochemiluminometric assay and C-peptide levels of Ն0.6 ng/mL (0.2 nmol/L) in the hypoglycemic setting (blood glucose Յ45 mg/dL and patient symptomatic) [5, 10, 11] . Marks and Teale do not provide assay specifics, but Marks and Teale recommend a cut-off of Ͼ5 IU/mL (34.7 pmol/L) for insulin, Ͼ0.9 ng/mL (0.3 nmol/L) for C-peptide, and blood glucose Ͻ54 mg/dL [4] .
We found a wide range of insulin and C-peptide levels in reported cases of sulfonylurea-induced hypoglycemia. If we apply the extremes of the above thresholds (insulin Ն6 or Ն3 IU/mL; C-peptide Ն0.9 or 0.6 ng/mL) to the values obtained in our study, 5 insulin levels fall below 6 IU/mL; 1 insulin level (Ͻ3.6 IU/mL) was possibly below 3 IU/mL; and 1 C-peptide level was below both 0.9 and 0.6 ng/mL. Table 4 shows the details of these cases.
All "sets" with blood glucose Ͻ49 mg/dL (2.7 mmol/L) had insulin levels Ն3 IU/mL (lowest 3.9 IU/mL; 1.3 nmol/L) and Cpeptide levels Ͼ0.9 ng/mL and Ն0.6 ng/mL (lowest 1.4 ng/mL; 0.5 nmol/L). Only 4 "sets" with blood glucose Ͻ49 mg/dL had insulin levels Ͻ6 IU/mL. These 4 "sets" are also shown in Table  4 . In "sets" with glucose Ն49 mg/dl, insulin was Ն22.5 IU/mL and C-peptide was Ն5.4 ng/mL in all but 1 "set". Table 5 provides details of all "sets" with blood glucose Ն49 mg/dL. Because Comments: Unknown if patient received therapy before levels were drawn. Levels obtained on 6 separate admissions for hypoglycemia. hypoglycemic symptoms may begin at glucose levels of Ͻ60 mg/dl [10] , clinicians initially faced with a hypoglycemic patient may not have the luxury of confirming that glucose is Ͻ49 mg/dL before levels are obtained. Before blood is obtained to measure insulin and C-peptide levels or before the diagnosis of hyperinsulinemia is entertained, patients may receive hypoglycemic therapy. However, even patients in the AFTER therapy group had elevated insulin and C-peptide levels, and they overlapped with insulin and C-peptide levels in the BEFORE therapy group. Most patients in the AFTER therapy group received intravenous glucose, but oral glucose, octreotide, and glucagon were also administered. Because there were only 7 patients in the AFTER therapy group, comparisons between these different hypoglycemic therapies was not possible. Interestingly, the patient in the article by Thoma had the 2 highest insulin levels, and the patient had the second highest C-peptide level of all the groups [30] . This may be related to the administration of 5 mg of intravenous glucagon [39, 40] . Glucagon stimulates insulin Number of exact C-peptide measurements 8/9 † 18/18 64/70 provided and used in calculations/ total number of C-peptide levels reported in group secretion, and intravenous glucagon administration may exaggerate insulin secretion in patients who are already hypersecreting insulin [39, 42] . This same dramatic response was not seen in the other patient who received glucagon, and the response, perhaps, is related to a smaller dose or route of administration [27] .
Some could argue that measuring insulin and C-peptide levels in hypoglycemia of uncertain cause is unnecessary when sulfonylurea screens are employed as part of the diagnostic work-up. However, not all sulfonylureas are detected by screens, and negative screens do not rule out sulfonylurea-induced hypoglycemia [21, 26, 30, 36, 43] . Additionally, quinine, non-sulfonylurea diabetic medications such as repalginide, and nateglinide can produce hypoglycemia with elevated insulin and C-peptide levels, but these medications do not appear on sulfonylurea screens [43] [44] [45] .
As with all article reviews there are limitations to this study. Our search was limited to Medline and articles written in English. The non-English literature may include other medications that would produce different results. However, our review included all sulfonylurea medications available in the US, all but one of those available in Canada (gliclazide), and almost half of those available in other countries [46] . A second limitation includes the values reported in the articles and that insulin and C-peptide levels were measured in several laboratories using different assays. It is possible that there were unreported insulin and C-peptide values that were below that individual laboratory detection limits. A third limitation is the small number of patients available for before and after therapy comparisons. Inclusion of additional levels might alter group comparisons. But given the large overlap between groups, we consider this unlikely. A fourth limitation is that we were limited to the medical details provided in the reports. It is possible some patients had unreported hepatic or renal failure that affected insulin and C-peptide levels. We cannot predict how these unrecognized conditions might alter our results. Finally, all patients did not have confirmatory studies to detect the presence of sulfonylureas. Although unlikely, given the history and laboratory findings, it is This "set" is also in Table 4 possible that some of these patients did not have sulfonylureainduced hypoglycemia.
CONCLUSIONS
There is a lack of information regarding insulin and C-peptide levels observed in sulfonylurea-induced hypoglycemia: so what constitutes "elevated" levels? Based on our study, with the exception of 1 insulin and 1 C-peptide level (both from the same "set" with an associated blood glucose level of 49 mg/dL), all insulin levels, based on our study, were Ն3.9 IU/mL (27.1 pmol/L), and all C-peptide levels were Ն1.4 ng/mL (0.5 nmol/L). Therefore, serum insulin Ն3.9 IU/mL and C-peptide Ն1.4 ng/mL in a patient with a blood glucose Ͻ49 mg/dl are consistent with sulfonylurea-induced hypoglycemia. Except for the one aforementioned "set," this relationship also held true for "sets" with blood glucose from Ն49 to Ͻ60 mg/dl. Glucose, insulin, and C-peptide levels tended to be higher if obtained after hypoglycemic therapy, but there is a large amount of overlap with levels obtained before therapy. Obtaining levels before or after hypoglycemic therapy did not affect interpretation of those levels because all "sets" in the BEFORE and AFTER therapy groups had insulin and C-peptide levels Ն3.9 IU/mL and Ն1.4 ng/mL respectively.
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